Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity.
暂无分享,去创建一个
Terrie Kitchner | Russell A Wilke | Catherine A McCarty | Terrie E. Kitchner | James G Linneman | R. Krauss | E. Kanin | C. McCarty | R. Wilke | T. Kitchner | J. Linneman | Ronald M Krauss | Ravi K Mareedu | Falgun M Modhia | Elenita I Kanin | Elenita I. Kanin | R. Mareedu | F. Modhia
[1] Russell A. Wilke,et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges , 2007, Nature Reviews Drug Discovery.
[2] M. Davidson,et al. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. , 2005, The American journal of cardiology.
[3] Claude Lenfant,et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. , 2002, Journal of the American College of Cardiology.
[4] Richard L Berg,et al. Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. , 2007, Basic & clinical pharmacology & toxicology.
[5] O. Henriksen,et al. Statin‐associated myopathy with normal creatine kinase levels , 2005 .
[6] H. Hoppeler,et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia , 2006, The Journal of pathology.
[7] J. Mckenney,et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. , 2006, The American journal of cardiology.
[8] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[9] E. Fleck,et al. Statin-associated focal myositis. , 2009, International journal of cardiology.
[10] W. Kirch,et al. Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin. , 2007, Clinical therapeutics.
[11] A. Windemuth,et al. Physiogenomic association of statin‐related myalgia to serotonin receptors , 2007, Muscle & nerve.
[12] M. Davidson. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance , 2004, Expert opinion on drug safety.
[13] Richard Platt,et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.
[14] P. Thompson,et al. An assessment of statin safety by muscle experts. , 2006, The American journal of cardiology.
[15] J. England,et al. Statin-Associated Myopathy with Normal Creatine Kinase Levels , 2002, Annals of Internal Medicine.
[16] J. Hokanson,et al. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. , 2007, Journal of clinical epidemiology.
[17] P. Thompson,et al. Statin-associated myopathy. , 2003, JAMA.
[18] Chengfeng Zhao,et al. Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository. , 2008, Basic & clinical pharmacology & toxicology.
[19] Russell A Wilke,et al. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage , 2005, Pharmacogenetics and genomics.
[20] Peggy L. Peissig,et al. Study of Effect of Drug Lexicons on Medication Extraction from Electronic Medical Records , 2004, Pacific Symposium on Biocomputing.